Piotr Wysocki recently shared on LinkedIn:

“Dear Colleagues,

I invite you to read a review article devoted to the clinical utility of endocrine and chemotherapy combinations in systemic breast cancer treatment.

Generally, the combination of these two distinct therapeutic strategies is considered inadvisable. However, such views are mainly based on studies conducted a few decades ago. Since then, many prospective and retrospective studies have emerged suggesting that the simultaneous use of chemotherapy and hormone therapy in patients with ER+ breast cancer can be a valuable therapeutic option, allowing for very effective disease control with an excellent safety profile.

The combination of chemotherapy and hormone therapy can be instrumental not only in middle and low-income countries, where profound limitations in access to modern, expensive therapies significantly worsen patient prognosis. Combined therapies also represent a therapeutic option for patients who have exhausted the effectiveness of classic systemic treatment strategies.”

Combination of chemotherapy and endocrine treatment in breast cancer — is it still a taboo?

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.